Thursday, March 15, 2018

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Secures Australian Importation Permit in Support of Research into Sol-gels

  • Research will be conducted at PACE, a leading pharmaceutical research center in Australia
  • PreveCeutical’s unique technology promises to be the first FDA-approved, CBD-based nose-to-brain delivery system using a Sol-gel platform
  • Groundbreaking technology outstrips the benefits of any other delivery mechanism
On March 13, 2018, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and Aurora Cannabis Inc. (OTCQB: ACBFF) (TSX: ACB) (FSE: 21P) announced that they had received three permits for the importation of cannabis plant material into Australia for research purposes. The permits were granted by the Australian Government’s Department of Health, allowing shipment from Canada by Aurora Cannabis Enterprises Inc., a wholly owned subsidiary of Aurora Cannabis Inc.
Preveceutical’s research program will be conducted at the University of Queensland’s Pharmacy Australia Centre of Excellence (“PACE”), a leading center for pharmaceutical research, education and commercialization. PACE has been granted the permits to import the dried cannabis flower and oils that will be used in the company’s innovative soluble gel (Sol-gel) drug delivery research program. It will be led by Dr. Harendra Parekh, chief research officer of PreveCeutical. The research team will test a range of cannabis strains to determine candidacy for the development and commercialization of cannabinoid-based Sol-gels.
The primary goal of the research program is to develop a nose-to-brain delivery system that will increase the bioavailability of active drug ingredients. The focus of the research is to apply Sol-gel technology to develop cannabinoid-based therapies for the relief of symptoms associated with pain, inflammation, seizures and neurological disorders. In a news release detailing the announcement, Stephen Van Deventer, chairman and CEO of PreveCeutical, said, “We are extremely excited to receive the Permits, allowing us to further our Sol-gel research program with the high quality cannabis products provided by Aurora. The goal of the Program is to cultivate a range of therapies that will benefit people with ailments such as epilepsy, pain and inflammation, safely and economically.”
“We see an important market for cannabis-based products that are more narrowly targeted at specific therapeutic areas but that are higher value add and being involved with initiatives such as PreveCeutical’s is part of our strategy to gain access to these types of products,” added Terry Booth, CEO of Aurora.
PreveCeutical believes that its cannabinoid-based nose-to-brain delivery technology, using a Sol-gel platform, will be the first to gain Food and Drug Administration approval. Its water soluable, alcohol free nasal formulation which will be developed for use by adults, children and people of certain beliefs.
PreveCeutical’s groundbreaking Sol-gel delivery system displays significant benefits over other contemporary delivery systems. It bypasses first pass metabolism in the stomach, intestines and liver, exhibiting a dramatic improvement in bioavailability, even compared to nasal sprays and alternative delivery mechanisms. Unlike other delivery systems, PreveCeutical’s Sol-gel delivery technology enables ease of application and provides long-lasting effects, all while eliminating negative side effects.
This latest research initiative comes on the back of established innovative solutions for preventive and curative therapies. The company’s first product, CELLB9®, is a Caribbean blue scorpion venom-based product that has been successfully marketed and distributed worldwide. PreveCeutical is currently in the development phase of a product based on this venom for the treatment, regulation and prevention of cancer progression. The company is also developing solutions based on the peptides derived from Caribbean blue scorpion venom for pain management, cancers, cardiovascular conditions, metabolic disorders and infectious diseases.
For more information, visit the company’s website at www.PreveCeutical.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)